Artwork

Konten disediakan oleh PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang dijelaskan di sini https://id.player.fm/legal.
Player FM - Aplikasi Podcast
Offline dengan aplikasi Player FM !

Peter H. Jones, MD, MNLA, R. Scott Wright, MD - Personalizing the Management of Hyperlipidemia: Addressing Unmet Needs Among High-Risk Patients With Atherosclerotic Cardiovascular Disease With Novel Lipid-Lowering Therapies

57:03
 
Bagikan
 

Manage episode 348510879 series 2602288
Konten disediakan oleh PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang dijelaskan di sini https://id.player.fm/legal.
Go online to PeerView.com/EPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Statin therapy is the cornerstone treatment for dyslipidemia, yet many patients are unable to attain recommended lipid goals with these oral therapies alone. PCSK9-targeting therapies, including monoclonal antibodies and small-interfering RNA, have been shown to reduce LDL-C levels by half, but questions surround the use of these agents and their associated outcomes. In this activity, based on a recent live symposium, leading experts discuss the latest data for these newer targeted therapies and offer evidence-based strategies to better individualize care to improve clinical outcomes, especially in patients with high ASCVD risk. Apply treatment guidelines for the management of hyperlipidemia, for both primary and secondary prevention of cardiovascular events, in patients with ASCVD; Identify the latest clinical evidence, mechanisms of action, and cardiovascular outcomes of approved and emerging non-statin, lipid-lowering therapies, especially PCSK9-targeting agents for managing hyperlipidemia in the ASCVD setting; and Individualize treatment regimens to reduce cardiovascular events in high-risk patients with hyperlipidemia consistent with consensus recommendations and recent clinical evidence available for novel lipid-lowering therapies.
  continue reading

407 episode

Artwork
iconBagikan
 
Manage episode 348510879 series 2602288
Konten disediakan oleh PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang dijelaskan di sini https://id.player.fm/legal.
Go online to PeerView.com/EPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Statin therapy is the cornerstone treatment for dyslipidemia, yet many patients are unable to attain recommended lipid goals with these oral therapies alone. PCSK9-targeting therapies, including monoclonal antibodies and small-interfering RNA, have been shown to reduce LDL-C levels by half, but questions surround the use of these agents and their associated outcomes. In this activity, based on a recent live symposium, leading experts discuss the latest data for these newer targeted therapies and offer evidence-based strategies to better individualize care to improve clinical outcomes, especially in patients with high ASCVD risk. Apply treatment guidelines for the management of hyperlipidemia, for both primary and secondary prevention of cardiovascular events, in patients with ASCVD; Identify the latest clinical evidence, mechanisms of action, and cardiovascular outcomes of approved and emerging non-statin, lipid-lowering therapies, especially PCSK9-targeting agents for managing hyperlipidemia in the ASCVD setting; and Individualize treatment regimens to reduce cardiovascular events in high-risk patients with hyperlipidemia consistent with consensus recommendations and recent clinical evidence available for novel lipid-lowering therapies.
  continue reading

407 episode

Semua episode

×
 
Loading …

Selamat datang di Player FM!

Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.

 

Panduan Referensi Cepat